Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin in Recurrent or Persistent Endometrial Carcinoma
NCT07139977Phase 2Recruiting
- Start
- Jul 2026
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin in endometrial cancer (EC). Started Jul 2026; status: recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07139977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07139977.